Cure My Disease

Don't miss your cure!

 Log in / Sign up

Text messages could help latino diabetes patients stick to meds

NCT ID NCT06000813

Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a mobile health tool called REACH-Español, which sends interactive text messages to help Latino adults with type 2 diabetes remember and take their medications. The trial included 70 participants who were at least 18 years old, identified as Latino or Hispanic, and had trouble sticking to their diabetes drugs. The goal was to see if the tool was easy to use and acceptable, and whether it could improve medication adherence and blood sugar control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
REACH-Español (interactive text message-based tool)
What this could lead to
If successful, this could provide a scalable, low-cost way to help Latino adults with type 2 diabetes better manage their medication and blood sugar levels.
What could go wrong
This was a small, early feasibility study with only 70 participants, so results may not apply to all Latino adults. The tool focuses on adherence, not a cure or major disease reversal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

70 people

The number who actually took part.

Started

Jun 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Type 2 diabetes mellitus * Have current or prior (since 2018) HbA1c ≥8.0% * Take at least one diabetes medication * Receive care at MGH- affiliated primary care practices (≥2 visits in the past 3 years) * ≥18 yrs * Identify as Latino and/or Hispanic * Speak and read in Spanish as preferred language * Willing and able to provide informed consent * Access to a mobile telephone with text messaging capability * Suboptimal diabetes medication adherence, assessed using the first 2 items in the Adherence to Refill and Medication Scale (ARMS-d) questionnaire combined: "How frequently do you forget or decide to not take your diabetes medications?" Participants who answer sometimes, almost always, and/or always will be considered eligible for the study. Exclusion Criteria: * Auditory limitations and/or inability to communicate orally * Inability to receive, read, or send a text message (assessed by a trained research assistant)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medication adherence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Medication Adherence type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medication adherence Type 2 diabetes (adult onset)

Contacts and locations

Locations

  • Massachusetts General Hospital Diabetes Research Center

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.